BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, September 25, 2023
Home » Blogs » BioWorld MedTech Perspectives » Rough start to 2016: J&J lays off 3,000

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Cardiovascular

Rough start to 2016: J&J lays off 3,000

Feb. 26, 2016
By Omar Ford
No Comments

2016Johnson & Johnson’s year did not get off to a great start. Not that last year was any better. I mean the company report lagging sales in its medical device’s market. But the start of 2016, led off with the Brunswick-N.J.-based company reporting that it would lay off about 3,000 people from its medical device division. Or about 6 percent of all medical device jobs and about 2.5 percent of J&J’s global workforce - for those of you that dig percents instead of raw numbers.

Most of the layoffs would come from the orthopedics, surgery and cardiovascular segments and result in an annual savings of nearly $1 billion.

The situation with J&J’s medical device segment has been a bit bleak to say the least. Within the first nine months of 2015, sales for the firm’s medical devices dropped 2.9 percent.

After J&J’s second quarter earnings were released, Glenn Novarro, an analyst with RBC Capital Markets pointed out the company needs more differentiated products for the medical devices segment (Medical Device Daily, July 16, 2015).

During the 2Q15 earnings call, the company revealed that it struggled in spine, trauma, diabetes and vision care. J&J said medical device sales fell 12.2 percent in 2Q15 to $6.36 billion, following the sale of the company’s Ortho-Clinical Diagnostics business to the Carlyle Group (Washington) for $4 billion. That unit had generated annual sales of almost $2 billion. Analysts said the $6.36 billion in device revenue was about $80 million below consensus.

Slumping sales were blamed by the firm’s  inability to keep up the pace with competitors like Medtronic plc., Boston Scientific Corp. and Abbott Laboratories (Abbott Park, Ill.).

The company has been in repair mode with its device’s segment for quite some time in my opinion. The company, once an innovator and a leader in the drug-eluting stent market, got out of the business all together and sold its Cordis unit to Cardinal Health Inc. for $1.944 billion in cash, or roughly $1.594 billion, net of the present value of tax benefits (MDD, March 3, 2015). Talk about a red flag.

J&J needs to put itself on a path of redemption now. It needs to get serious about med-tech and medical devices. Some strong acquisitions are sorely needed to boost the ailing segment and get it back on the right path.

 

 

 

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing